LICENSE AGREEMENTS AND COMMITMENTS - License Agreements (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) agreement	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) agreement	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Financial statement information
Accrued liabilities, current	$ 17,067,000		$ 17,067,000		$ 12,540,000
Accrued liabilities, noncurrent	2,250,000		2,250,000		2,100,000
Gross intangible assets related to Danyelza	$ 1,574,000		$ 1,574,000		1,663,000
MSK
Agreements
Number of license agreements | agreement	2		2
MSK License Agreement
Financial statement information
Cash paid			$ 1,263,000	$ 450,000
Expense	$ 1,083,000	$ 210,000	1,760,000	210,000
Accrued liabilities, current	1,683,000		1,683,000		1,486,000
Accrued liabilities, noncurrent	1,950,000		1,950,000		1,650,000
Milestones
Maximum Clinical Milestones	2,450,000		2,450,000
Maximum Regulatory Milestones	9,000,000		9,000,000
Maximum Sales-based Milestones	20,000,000		20,000,000
CD33 License Agreement
Financial statement information
Cash paid				100,000
Accrued liabilities, current	150,000		150,000
Accrued liabilities, noncurrent	300,000		300,000		450,000
Milestones
Maximum Clinical Milestones	550,000		550,000
Maximum Regulatory Milestones	500,000		500,000
Maximum Sales-based Milestones	7,500,000		7,500,000
MabVax Agreement
Financial statement information
Expense		$ 10,000		10,000
Milestones
Maximum Clinical Milestones	200,000		200,000
Maximum Regulatory Milestones	1,200,000		1,200,000
SADA License Agreement
Financial statement information
Cash paid			1,000,000	$ 1,000,000
Accrued liabilities, current	605,000		605,000		$ 1,605,000
Milestones
Maximum Clinical Milestones	4,730,000		4,730,000
Maximum Regulatory Milestones	18,125,000		18,125,000
Maximum Sales-based Milestones	23,750,000		$ 23,750,000
Period for which all time-based milestones coming due have been accrued			36 months
Time-based milestone payments coming due, Accrued liabilities	$ 605,000		$ 605,000